Protocolo in silico para el diseño de potenciales inhibidores de la proteasa principal 3clpro del nuevo coronavirus sars-cov-2
To date, around 62 million positive cases of COVID-19 have been reported globally. The International Committee on Taxonomy of Viruses (ICTV) named this coronavirus as SARS-CoV-2. There are several crucial proteins involved in the SARS-CoV-2 replication cycle, one of those is the Mpro main protease p...
- Autores:
-
Hayek Orduz, Yasser
- Tipo de recurso:
- Trabajo de grado de pregrado
- Fecha de publicación:
- 2020
- Institución:
- Universidad de los Andes
- Repositorio:
- Séneca: repositorio Uniandes
- Idioma:
- spa
- OAI Identifier:
- oai:repositorio.uniandes.edu.co:1992/51655
- Acceso en línea:
- http://hdl.handle.net/1992/51655
- Palabra clave:
- COVID-19 (Enfermedad)
Dinámica molecular
Enzimas proteolíticas
Ingeniería
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/4.0/
id |
UNIANDES2_b59d3d8b2025ca747d0ea3b16f683b2f |
---|---|
oai_identifier_str |
oai:repositorio.uniandes.edu.co:1992/51655 |
network_acronym_str |
UNIANDES2 |
network_name_str |
Séneca: repositorio Uniandes |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Protocolo in silico para el diseño de potenciales inhibidores de la proteasa principal 3clpro del nuevo coronavirus sars-cov-2 |
title |
Protocolo in silico para el diseño de potenciales inhibidores de la proteasa principal 3clpro del nuevo coronavirus sars-cov-2 |
spellingShingle |
Protocolo in silico para el diseño de potenciales inhibidores de la proteasa principal 3clpro del nuevo coronavirus sars-cov-2 COVID-19 (Enfermedad) Dinámica molecular Enzimas proteolíticas Ingeniería |
title_short |
Protocolo in silico para el diseño de potenciales inhibidores de la proteasa principal 3clpro del nuevo coronavirus sars-cov-2 |
title_full |
Protocolo in silico para el diseño de potenciales inhibidores de la proteasa principal 3clpro del nuevo coronavirus sars-cov-2 |
title_fullStr |
Protocolo in silico para el diseño de potenciales inhibidores de la proteasa principal 3clpro del nuevo coronavirus sars-cov-2 |
title_full_unstemmed |
Protocolo in silico para el diseño de potenciales inhibidores de la proteasa principal 3clpro del nuevo coronavirus sars-cov-2 |
title_sort |
Protocolo in silico para el diseño de potenciales inhibidores de la proteasa principal 3clpro del nuevo coronavirus sars-cov-2 |
dc.creator.fl_str_mv |
Hayek Orduz, Yasser |
dc.contributor.advisor.none.fl_str_mv |
González Barrios, Andrés Fernando Vásquez Jiménez, Andrés Felipe |
dc.contributor.author.none.fl_str_mv |
Hayek Orduz, Yasser |
dc.contributor.jury.none.fl_str_mv |
Salcedo Galán, Felipe |
dc.subject.armarc.none.fl_str_mv |
COVID-19 (Enfermedad) Dinámica molecular Enzimas proteolíticas |
topic |
COVID-19 (Enfermedad) Dinámica molecular Enzimas proteolíticas Ingeniería |
dc.subject.themes.none.fl_str_mv |
Ingeniería |
description |
To date, around 62 million positive cases of COVID-19 have been reported globally. The International Committee on Taxonomy of Viruses (ICTV) named this coronavirus as SARS-CoV-2. There are several crucial proteins involved in the SARS-CoV-2 replication cycle, one of those is the Mpro main protease protein, also known as the 3CLpro protein. Due to the pandemic, the information about the main protease is increasing day by day. However, there are knowledge gaps involved during important processes such as dimerization. On the other hand, to date, no powerful tools have been developed that allow a quick search of 3CLpro inhibitors, such as pharmacophore models. In other studies, protease inhibitor pharmacophoric models have been designed, but none have been used in virtual screening processes due to the lack of model validation. To fill these knowledge gaps, in this study, a protocol composed of molecular dynamics (MD) simulations, molecular docking, free energy calculations and pharmacophore modeling was executed. In this protocol, a molecular dynamics simulation of Mpro protein in apo form and 55 molecular dynamics simulations of Mpro protein-ligand complexes with several inhibitors were performed. The molecular dynamics simulations were employed to design two protein-ligand based pharmacophore models. One of these two models includes the electrophilic group feature, a novel feature in pharmacophore modeling. It?s expected to use the pharmacophore models to design SARS-CoV-2 Mpro protease inhibitors that can function as a treatment for COVID-19. |
publishDate |
2020 |
dc.date.issued.none.fl_str_mv |
2020 |
dc.date.accessioned.none.fl_str_mv |
2021-08-10T18:36:43Z |
dc.date.available.none.fl_str_mv |
2021-08-10T18:36:43Z |
dc.type.spa.fl_str_mv |
Trabajo de grado - Pregrado |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
dc.type.content.spa.fl_str_mv |
Text |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/TP |
format |
http://purl.org/coar/resource_type/c_7a1f |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/1992/51655 |
dc.identifier.pdf.none.fl_str_mv |
23523.pdf |
dc.identifier.instname.spa.fl_str_mv |
instname:Universidad de los Andes |
dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional Séneca |
dc.identifier.repourl.spa.fl_str_mv |
repourl:https://repositorio.uniandes.edu.co/ |
url |
http://hdl.handle.net/1992/51655 |
identifier_str_mv |
23523.pdf instname:Universidad de los Andes reponame:Repositorio Institucional Séneca repourl:https://repositorio.uniandes.edu.co/ |
dc.language.iso.none.fl_str_mv |
spa |
language |
spa |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 |
eu_rights_str_mv |
openAccess |
dc.format.extent.none.fl_str_mv |
107 hojas |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidad de los Andes |
dc.publisher.program.none.fl_str_mv |
Ingeniería Química |
dc.publisher.faculty.none.fl_str_mv |
Facultad de Ingeniería |
dc.publisher.department.none.fl_str_mv |
Departamento de Ingeniería Química y de Alimentos |
publisher.none.fl_str_mv |
Universidad de los Andes |
institution |
Universidad de los Andes |
bitstream.url.fl_str_mv |
https://repositorio.uniandes.edu.co/bitstreams/2648167e-aaed-44be-968b-88d368df36e7/download https://repositorio.uniandes.edu.co/bitstreams/296e70f5-419e-4231-9411-315711485cb9/download https://repositorio.uniandes.edu.co/bitstreams/d7b6b15e-374c-4523-a767-392b4a39210d/download |
bitstream.checksum.fl_str_mv |
e08e67e68d48238c565a3c862fe64c07 3dae62288af12049ad768f3009765ff5 339e4958368f1bcc043b0fe0f7da4ff7 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio institucional Séneca |
repository.mail.fl_str_mv |
adminrepositorio@uniandes.edu.co |
_version_ |
1812133855859048448 |
spelling |
Al consultar y hacer uso de este recurso, está aceptando las condiciones de uso establecidas por los autores.http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2González Barrios, Andrés Fernando007ff982-0b16-4d2e-b379-19c280935a79400Vásquez Jiménez, Andrés Felipevirtual::3789-1Hayek Orduz, Yasser54366ad6-bcd1-4bc0-8653-17dcaa614687500Salcedo Galán, Felipe2021-08-10T18:36:43Z2021-08-10T18:36:43Z2020http://hdl.handle.net/1992/5165523523.pdfinstname:Universidad de los Andesreponame:Repositorio Institucional Sénecarepourl:https://repositorio.uniandes.edu.co/To date, around 62 million positive cases of COVID-19 have been reported globally. The International Committee on Taxonomy of Viruses (ICTV) named this coronavirus as SARS-CoV-2. There are several crucial proteins involved in the SARS-CoV-2 replication cycle, one of those is the Mpro main protease protein, also known as the 3CLpro protein. Due to the pandemic, the information about the main protease is increasing day by day. However, there are knowledge gaps involved during important processes such as dimerization. On the other hand, to date, no powerful tools have been developed that allow a quick search of 3CLpro inhibitors, such as pharmacophore models. In other studies, protease inhibitor pharmacophoric models have been designed, but none have been used in virtual screening processes due to the lack of model validation. To fill these knowledge gaps, in this study, a protocol composed of molecular dynamics (MD) simulations, molecular docking, free energy calculations and pharmacophore modeling was executed. In this protocol, a molecular dynamics simulation of Mpro protein in apo form and 55 molecular dynamics simulations of Mpro protein-ligand complexes with several inhibitors were performed. The molecular dynamics simulations were employed to design two protein-ligand based pharmacophore models. One of these two models includes the electrophilic group feature, a novel feature in pharmacophore modeling. It?s expected to use the pharmacophore models to design SARS-CoV-2 Mpro protease inhibitors that can function as a treatment for COVID-19.Hasta la fecha, en el mundo se han reportado alrededor de 62 millones de casos positivos de COVID-19. El Comité Internacional de Taxonomía de Virus (ICTV) le dio el nombre de SARS-CoV-2 a este coronavirus. Existen varias proteínas importantes en el ciclo de replicación de SARS-CoV-2 y una de ellas es la proteasa principal Mpro, también conocida como 3CLpro. Debido al avance vertiginoso de la pandemia, la información encontrada sobre la proteasa principal va en aumento día tras día. Sin embargo, existen vacíos de conocimiento en procesos importantes de la proteasa como lo es la dimerización. Por otro lado, hasta el día de hoy, no se han desarrollado herramientas poderosas que permitan una búsqueda ágil de inhibidores de 3CLpro, como pueden ser los modelos de farmacóforos. En otras investigaciones, se han diseñado modelos de farmacóforos de inhibidores de la proteasa, pero ninguno se ha utilizado en procesos de screening virtual debido a la falta de validación del modelo. Para llenar esos vacíos de conocimiento en el presente estudio se ejecutó un protocolo compuesto por simulaciones de dinámica molecular (MD), docking molecular, cálculos de energía libre y modelamiento de farmacóforos. Las simulaciones de dinámica molecular se emplearon para generar 2 modelos de farmacóforos basados en proteína-ligando. Uno de estos dos modelos contiene la característica de grupo electrofílico, una característica novedosa en el modelamiento de farmacóforos. Se espera utilizar los modelos de farmacóforos para diseñar inhibidores de la proteasa Mpro de SARS-CoV-2 que puedan funcionar como tratamiento para COVID-19.Ingeniero QuímicoPregrado107 hojasapplication/pdfspaUniversidad de los AndesIngeniería QuímicaFacultad de IngenieríaDepartamento de Ingeniería Química y de AlimentosProtocolo in silico para el diseño de potenciales inhibidores de la proteasa principal 3clpro del nuevo coronavirus sars-cov-2Trabajo de grado - Pregradoinfo:eu-repo/semantics/bachelorThesishttp://purl.org/coar/resource_type/c_7a1fhttp://purl.org/coar/version/c_970fb48d4fbd8a85Texthttp://purl.org/redcol/resource_type/TPCOVID-19 (Enfermedad)Dinámica molecularEnzimas proteolíticasIngeniería201412398Publication3160c3f9-3f1b-4545-a667-233105f42888virtual::3789-13160c3f9-3f1b-4545-a667-233105f42888virtual::3789-1https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000769410virtual::3789-1ORIGINAL23523.pdfapplication/pdf72854140https://repositorio.uniandes.edu.co/bitstreams/2648167e-aaed-44be-968b-88d368df36e7/downloade08e67e68d48238c565a3c862fe64c07MD51TEXT23523.pdf.txt23523.pdf.txtExtracted texttext/plain299709https://repositorio.uniandes.edu.co/bitstreams/296e70f5-419e-4231-9411-315711485cb9/download3dae62288af12049ad768f3009765ff5MD54THUMBNAIL23523.pdf.jpg23523.pdf.jpgIM Thumbnailimage/jpeg7314https://repositorio.uniandes.edu.co/bitstreams/d7b6b15e-374c-4523-a767-392b4a39210d/download339e4958368f1bcc043b0fe0f7da4ff7MD551992/51655oai:repositorio.uniandes.edu.co:1992/516552024-03-13 12:31:27.619http://creativecommons.org/licenses/by-nc-nd/4.0/open.accesshttps://repositorio.uniandes.edu.coRepositorio institucional Sénecaadminrepositorio@uniandes.edu.co |